Aristotle University Of Thessaloniki (AUTH)
Διερεύνηση των μεταβολών της συγκέντρωσης της καρδιακής τροπονίνης Ι (cTnl) στον ορό του αίματος σκύλων με ενδοκάρδωση των κολποκοιλιακών βαλβίδων
Abstract
dc:descriptionEndocardiosis (myxomatous valve degeneration, degenerative valvular disease) is the most common condition among canine cardiac diseases, its frequency ranging from 75-80%. It is also the most frequent cause of cardiac insufficiency in dogs, representing almost 75% of all heart failure cases.Up to date the diagnosis of endocardiosis (MVD) was based on the findings of physical examination, electrocardiography and diagnostic imaging (thoracic radiographs, cardiac ultrasonography), which are not always helpful in selecting the appropriate treatment or establishing the case prognosis. In addition, some of these diagnostic tests are cost-prohibitive or not widely available in clinical practice.The use of specific biomarkers as an additional diagnostic tool for cardiac diseases of companion animals is rapidly expanding in clinical practice, as it has already been established for several other systemic abnormalities (i.e. renal, liver or endocrine disease). Currently the measurement of cardiac troponin I and T (cTnI, cTnT) in the serum of affected animals is recognized as a sensitive method for assessing myocardial insufficiency, regardless of its inciting cause, and has replaced previously used tests, such as the measurement of serum creatine kinase MB (CKMB) and lactic dehydrogenase 1 (LD1) isoenzymes.The objective of this study was to evaluate cTnI, total (CK) and myocardial creatine kinase (CKMB) changes in dogs with MVD and to correlate them with the clinical staging, the findings of other diagnostic investigation tests (arterial blood pressure, mean electrical cardiac axis, cardiac vertebral index and left ventricle fractional shortening) and the response to treatment. The serial determination of cTnI changes was of particular importance due to its high sensitivity and specificity in diagnosing heart disease in humans and companion animals. A total of 56 dogs, diagnosed with MVD were included in the study. According to the clinical signs, the findings of the initial diagnostic evaluation and a modified classification scheme, based on the guidelines of the International Small Animal Cardiac Health Council (1995), dogs were allocated into three groups: 22 dogs (39.28%) from the study population were allocated to group I (asymptomatic animals), 18 (32.14%) to group II (mild to moderate signs of congestive heart failure) and 16 (28.57%) to group III (severe signs of congestive heart failure). An age and breed matched control group (n=30) was used for comparison.In order to be included in the study dogs had to fulfill the following criteria: a) to have clinical signs compatible with MVD, the diagnosis of which was made by the detection of an auscultable regurgitant murmur and confirmed by 2-D echocardiography (thickened, nodular or prolapsing mitral valve leaflets), b) to have not been treated with cardiovascular medication c) to have not presented clinical signs and/or clinicopathological abnormalities indicative of a systemic disease, d) to test serologically and parasitologically negative for Dirofilaria immitis.Upon admission, all 56 dogs underwent a complete physical and cardiological examination. The overall clinical assessment was done by evaluating the presence and severity of several clinical signs (cough, exercise intolerance, syncope, weakness, dyspnea, tachypnea, orthopnea, cyanosis, abnormal lung sounds, weak femoral pulse, ascites, venous jugular pulse) and by applying a scoring system ranging from 0 to 3 (0-absent, 1-mild, 2-moderate, 3-severe). The total score for each of the dogs was calculated by adding the mean score of the two examiners for each clinical parameter.Diagnostic investigation also included the measurement of arterial blood pressure, electrocardiography, thoracic radiography and 2-D echocardiography. Arterial blood pressure was measured 5 consecutive times to obtain the mean value, in order to minimize the effects of physical stress. A standard six-lead electrocardiogram and two sets of thoracic radiographs (right lateral and ventrodorsal views) were obtained from each dog to search for arrhythmias and to calculate the vertebral heart score (VHS), respectively. A 2-D color Doppler echocardiogram was used to confirm the diagnosis and to assess the cardiac anatomical changes and left ventricular shortening fraction (LVSF).Blood samples (5 ml) were collected from all 56 dogs for CBC (whole blood), Dirofilaria immitis antigen detection and routine biochemistry (serum). A serum aliquot was also saved to measure the creatine kinase MB isoenzyme (CKMB) activity and cTnI concentration. The sample for the common laboratory parameters was processed immediately, whereas that reserved for CKMB and cTnI measurement was stored at -80oC until shipment, which was done approximately within 3 months for each sample batch. A complete urinalysis was also performed in all 56 dogs.The study lasted for six months and during this follow-up period of each of the dogs serum samples for biochemical testing were obtained every 15 days. Clinical progression and response to treatment were evaluated every 15 days whereas radiographic and echocardiographic reevaluation was done every two months.There were no significant differences upon comparison of the four study groups with respect to their breed, sex, age and body weight. Mean body weight changes were not significant in all groups throughout the study despite a decreasing tendency that was noted in group III dogs. In groups I and II there were no significant changes regarding the vertebral heart score (VHS) during the observation period, however a significant upwards trend in VHS values was seen in group III. With respect to the LVSF, there were no significant changes in all three animal groups throughout the 6-month period. Upon admission of the animals, CK activity exceeded the upper reference limit in one group III dog, which was the only abnormal value recorded through the entire study. In groups I and III there were no significant changes in CK activity during the study, in contrast to group II, where it decreased significantly. In the asymptomatic (group I) dogs CKMB was not different than in the clinically healthy controls. However, there was a significant decrease of CKMB activity within the first 2 weeks of the study in group III dogs. Despite the variations observed during the study period, no significant temporal changes could be noticed within any of the groups (Figure 2). An increased cTnI value was noticed in more than one-third (36.7%) of the asymptomatic dogs and in almost all the other dogs (group II-94.4%, group III-100%) at the beginning of the observation period. There was a significant decrease of cTnI values during the first two weeks of the study, mainly attributed to the changes observed in group III dogs and corresponding to the initiation of therapy and the clinical stabilization of the animals. In groups I and III no significant temporal changes could be detected despite the fluctuation of cTnI values throughout the observation period. In particular, in group III there was a sudden cTnI increase at time point 5 (2.5 months after the beginning of the study), caused by the sudden clinical deterioration in one of the animals, due to the rupture of mitral valve chordae tendinae and acute decompensation. By contrast there was steady and significant temporal increase of serum cTnI values in group II animals. Serum CKMB concentration was strongly and positively correlated with the severity of clinical signs only in group III. In contrast, cTnI was very strongly and positively correlated with the severity of clinical signs in all dog groups from the beginning and throughout the entire study period. Finally, upon evaluation of the association between changes in serum CKMB and cTnI concentration, a strongly positive correlation of the two parameters existed only in group III dogsIn conclusion, the serial measurement of cTnI in the serum of dogs with MVD is a useful tool in the long term management of cases and the monitoring of treatment response, because its concentration is readily affected from changes in the clinical presentation of the affected dogs. The diagnosis of heart failure will always depend on a comprehensive approach comprising history, clinical, laboratory and technical examinations, with cardiac biomarker testing representing just one important modality. The development of a blood test that detects and evaluates cardiac disease is an attractive prospective that could improve the long term management of such cases, identifying those for which further investigation or medical treatment is warranted.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Dasopoulou, Anastasia
- Δασοπούλου, Αναστασία
Subjects
dc:subject × 15Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/28287